Evidence brief · printable

Sickle Cell Disease evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Sickle Cell Disease: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/sickle-cell-disease.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Hydroxyurea 7 trials
  • Crizanlizumab 3 trials
  • Fludarabine 3 trials
  • Cyclophosphamide 2 trials
  • Osivelotor (GBT021601) 2 trials
  • Alemtuzumab 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Education, coaching and self-management 25 trials · 21 completed · 9 with results
  • Vitamin D 6 trials · 6 completed · 3 with results
  • Psychotherapy, counselling and peer support 10 trials · 5 completed · 2 with results
  • Mindfulness, meditation and relaxation 13 trials · 10 completed · 1 with results
  • Care coordination, navigation and outreach 8 trials · 7 completed · 1 with results
  • Cognitive behavioural and related therapies 5 trials · 3 completed · 1 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • L-Arginine

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects… NCT07656415
  • A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell… NCT06546670
  • Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease NCT07708350
  • mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria NCT06318143
  • Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain NCT06374238
  • SMYLS Multi-site Trial NCT06035939

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Among 24 trials of supplements and nutraceuticals found, none measured pain 43 trials of other approaches did
  • Among 31 trials of mind-body and psychological approaches found, none measured inflammation and other biomarkers 19 trials of other approaches did
  • Among 24 trials of supplements and nutraceuticals found, none measured mood, anxiety and wellbeing 19 trials of other approaches did
  • Oxygen, light, temperature and manual therapies: pain 7 trials, no results posted yet
  • Other devices and digital tools: pain 7 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (171 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.